Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biopharmaceutical company pioneering treatments for aggressive central nervous system cancers. This page provides investors and medical stakeholders with timely updates on the company’s groundbreaking therapies, including Berubicin for glioblastoma and TPI 287 for advanced CNS tumors.
Access consolidated updates on clinical trial progress, FDA designations, and strategic partnerships. Our news feed covers critical developments in the company’s pipeline, including Phase II results for Berubicin – the first anthracycline to cross the blood-brain barrier – and preclinical advancements for TPI 287’s microtubule-stabilizing mechanism.
Key coverage areas include regulatory milestones, peer-reviewed research publications, and collaborations with leading institutions like MD Anderson Cancer Center. Bookmark this page for verified updates on CNS Pharmaceuticals’ efforts to address unmet needs in neuro-oncology through innovative science and targeted drug development.
CNS Pharmaceuticals (NASDAQ:CNSP) reported its full year 2024 financial results, highlighting a net loss reduction to $14.9 million from $18.9 million in 2023. The company's primary Berubicin trial for glioblastoma multiforme (GBM) did not meet its primary endpoint of statistical superiority in overall survival compared to Lomustine.
Research and development expenses decreased to $9.3 million from $14.1 million, while general and administrative expenses increased to $5.6 million from $4.8 million. The company holds approximately $6.5 million in cash and raised an additional $9.9 million through stock sales, providing operational funding into Q1 2026.
Moving forward, CNSP is pivoting to develop TPI 287, a novel abeotaxane licensed from Cortice Biosciences in July 2024. TPI 287 has shown promising clinical efficacy in GBM treatments and has received Orphan Drug Designation, with plans to engage FDA for potential registration study design in 2025.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced the primary analysis of its clinical trial for Berubicin, an anthracycline treatment for recurrent Glioblastoma Multiforme (GBM). The study compared Berubicin to Lomustine, a standard GBM treatment.
Key findings show that while Berubicin did not demonstrate statistically significant superiority in overall survival (the primary endpoint), it showed comparable clinical outcomes to Lomustine across multiple endpoints. Notably, Berubicin displayed no cardiotoxicity, a common limitation with other anthracyclines, and maintained a favorable safety profile.
The drug is significant as the first anthracycline proven to extensively cross the blood-brain barrier. The company is continuing analysis of outcomes, including advanced imaging review and clinical endpoints. Additionally, CNS Pharmaceuticals is developing TPI 287, a novel taxane with published clinical efficacy data in GBM treatment.
CNS Pharmaceuticals (NASDAQ:CNSP) has provided an update on its financial position and NASDAQ listing status. The company reports a current cash position of $14 million, which is expected to fund operations into 2026. This runway will support their ongoing global Berubicin trial, with primary data analysis anticipated in the first half of 2025.
The company has implemented a reverse stock split to maintain NASDAQ compliance with minimum bid price requirements. Additionally, CNS Pharmaceuticals plans to initiate their TPI 287 clinical program with first patient consent targeted before year-end.
According to CEO John Climaco, the company is positioned for what they believe will be their most transformational year, with key milestones expected in the second half of 2025.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 18th Annual European Life Sciences CEO Forum in Zurich, Switzerland.
The company's CEO, John Climaco, will deliver a presentation on Wednesday, February 26, 2025, at 3:20 PM CET / 9:20 AM EST. Management will also be available for one-on-one meetings with qualified registered investors during the conference.
A video webcast of the presentation will be accessible on-demand through the conference presenters portal for registered attendees. The presentation represents an opportunity for CNS Pharmaceuticals to showcase its developments in primary and metastatic cancer treatments.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. CEO John Climaco presented the company's top five investment highlights for 2025. The presentation is now available for viewing on the company's website and through the conference platform.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced a 1-for-50 reverse stock split effective February 21, 2025. The company's stock will continue trading on Nasdaq under the same symbol 'CNSP' but with a new CUSIP number: 18978H409.
The reverse split is primarily aimed at increasing the per-share trading price and achieving compliance with Nasdaq's minimum share price requirements. For every 50 shares currently held, stockholders will receive one share. The company will make cash payments in lieu of fractional shares.
All outstanding warrants and equity-based awards will be proportionally adjusted by dividing underlying shares by 50 and multiplying exercise/conversion prices by 50. The par value remains at $0.001 per share, and the authorized share count stays at 300 million shares.
CNS Pharmaceuticals (NASDAQ:CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit in Boston, MA, from February 18-20, 2025. Chief Medical Officer Sandra Silberman, MD, PhD, will present on February 20 at 10:45 AM ET, discussing novel formulations of anthracycline and taxane that can cross the Blood-Brain Barrier (BBB).
The company's lead program, Berubicin, has shown efficacy in Phase 1 and completed enrollment with 252 patients in its pivotal study versus Lomustine for GBM treatment. Primary analysis data is expected in the first half of 2025. CNS is also advancing TPI 287, an abeotaxane showing significant activity in Phase 1b studies.
The FDA has granted Fast Track Designation for Berubicin, allowing more frequent agency interactions, and Orphan Drug Designation for treating malignant glioma, potentially providing seven years of marketing exclusivity upon NDA approval.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the BIO CEO & Investor Conference in New York, NY.
The company's CEO, John Climaco, is scheduled to present on Monday, February 10, 2025, at 1:15 PM ET in the Royale Room. The conference runs from February 10-11, 2025.
Management will be available for one-on-one meetings with conference attendees, who can schedule meetings through the BIO CEO attendee portal. Interested parties can find additional conference information at bcic.bio.org.
CNS Pharmaceuticals (NASDAQ:CNSP) announces a Virtual Analyst & Investor Day scheduled for December 11th, 2024, from 11:30 AM to 1:00 PM ET. The event will feature discussions on Glioblastoma Multiforme (GBM), an aggressive brain cancer with only 14-16 months average survival post-diagnosis.
The presentation will include key company executives and renowned medical experts: CEO John Climaco, CMO Sandra Silberman, VP of Clinical Operations Zena Muzyczenko, along with KOLs Michael Weller, Samuel Goldlust, and Erin Dunbar.
The agenda includes an overview of Berubicin and its clinical development program, plus discussion of their second asset, TPI 287. The event will be accessible via webcast on the company's website, with replay available for 90 days.
CNS Pharmaceuticals (NASDAQ:CNSP) presented updated results from its ongoing pivotal study comparing Berubicin versus Lomustine in adult patients with recurrent glioblastoma (GBM). The study has enrolled 239 patients, with comparable demographics between treatment arms. Key findings show higher study completion rates in the Berubicin arm (84.7% vs 78.9%) and lower withdrawal rates (11.0% vs 19.7%) compared to Lomustine. Safety profiles were similar between arms, with Berubicin showing slightly higher rates of anemia and neutropenia, while Lomustine had more thrombocytopenia cases. The company expects to report primary analysis data in the first half of 2025.
FAQ
What is the current stock price of CNS Pharmaceuticals (CNSP)?
What is the market cap of CNS Pharmaceuticals (CNSP)?
